A new type of SARS-CoV-2 antigen test that relies on single molecule array technology may be able to help clinicians identify which patients are most likely to experience severe disease.
Keeping you up to date on recent developments in orthopedics, including: New drug shown to improve bone growth in children with achondroplasia; Failure to calibrate for ethnicity in fracture epidemiology would do more harm than good; Muscle aging: Stronger for longer; After Medicaid expansion, 'unmet need' for joint replacement surgery.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), drug-induced liver injury (DILI) is the leading cause of acute liver failure in the U.S. It is also a leading cause of drug failure in clinical trials. Now, researchers have used liver organoids to develop a polygenic risk score that could predict the risk of liver toxicity for multiple different drugs, regardless of the underlying mechanism.
BioWorld looks at translational medicine, including: Angiopoietin trouble can lead to lymphedema; Toxicity, infectivity separate issues for prion protein.
An Australian study led by University of Melbourne scientists has identified a previously unknown role for the hepatokine, sparc-related modular calcium-binding protein 1 (SMOC1), in suppressing hepatic glucose production.
Keeping you up to date on recent developments in oncology, including: Algorithm improves prediction of hepatocellular carcinoma following hepatitis-driven cirrhosis; MTOR-targeting metabolite discovered; Dartmouth’s Thayer School wins NIH grant.
Keeping you up to date on recent developments in neurology, including: Sleep quality linked to onset; progression of Alzheimer's; Using magnetic resonance elastography to detect epilepsy; How can hearing loss cause dementia?
BioWorld looks at translational medicine, including: MTOR-targeting metabolite discovered; AKG for A-OK aging; Benzodiazepine and barbiturate binding to GABA-A; Giving misfolded proteins a second chance; Agrin-culture grows cartilage; SCAD vs. plaques in heart attacks.
An Australian study led by University of Melbourne scientists has identified a previously unknown role for the hepatokine, sparc-related modular calcium-binding protein 1 (SMOC1), in suppressing hepatic glucose production. The investigators reported their results in the Sept. 2, 2020, edition of Science Translational Medicine.
RSS
